Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pCcdEbT
via IFTTT